DEF: BioSig Pivots to Tokenized Gold, Faces Major Dilution

BioSig Technologies, Inc. seeks shareholder approval for a strategic pivot into tokenized finance via the acquisition of Streamex Exchange Corporation, alongside significant capital raises and governance changes, leading to substantial dilution for existing shareholders.

Summary

• BioSig Technologies, Inc. has acquired Streamex Exchange Corporation, a pre-revenue blockchain-based tokenized gold platform, and is seeking shareholder approval for related matters.
• The acquisition involves issuing approximately 109,070,079 shares of BioSig common stock and one Super Voting Preferred Stock share to Streamex shareholders, who will collectively own 75% of the fully diluted shares of the combined entity if approved.
• Existing BioSig shareholders will retain approximately 25% of the fully diluted shares post-acquisition approval.
• If shareholder approval for the acquisition is not obtained within six months of the May 28, 2025 closing, the exchange ratio for Streamex shares will adjust from 1.0 to 1.25, increasing dilution for BioSig shareholders.
• The company is seeking approval to issue shares underlying $100 million in convertible debentures to Yorkville, and potentially up to $1 billion under a Standby Equity Purchase Agreement (SEPA) with Yorkville.
• Shareholder approval is also sought to increase authorized common stock from 200 million to 500 million shares and to classify the board of directors into three classes with staggered three-year terms.
• Streamex reported a net loss of approximately CAD$1.7 million for the period from incorporation (April 5, 2024) to December 31, 2024, and had an accumulated deficit of CAD$1.9 million as of March 31, 2025, with a 'going concern' qualification from its auditors.
• For the three months ended March 31, 2025, Streamex generated CAD$283,831 in revenue and incurred a net loss of CAD$215,224.
• Pro forma combined financial statements show a net loss of approximately $4.4 million for the three months ended March 31, 2025, and $18.8 million for the year ended December 31, 2024.
• The acquisition resulted in the recognition of $47.5 million in intangible assets and $57.8 million in goodwill, with the exchangeable shares classified as a $105.5 million derivative liability due to variable settlement features.

Sentiment

Score: 2

Explanation: The filing outlines a highly dilutive acquisition of a pre-revenue, loss-making company with a 'going concern' qualification, coupled with plans for massive, potentially highly dilutive, capital raises in a speculative and unproven new industry. This represents a significant increase in risk and a substantial negative impact on existing shareholder value.

Positives

• The acquisition aims to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth in tokenized finance and real-world asset digitization.
• The strategic pivot provides access to adjacent markets and digital asset infrastructure, potentially creating new recurring or transactional revenue streams less dependent on traditional biotech cycles.
• Streamex's leadership brings technology and digital finance expertise, complementing BioSig's biotech knowledge and enhancing the management team's overall execution capacity.
• The combined company could be more attractive to a broader investor base due to exposure to multiple high-growth sectors, potentially improving capital markets positioning and supporting a re-rating or increase in trading multiples.
• The Standby Equity Purchase Agreement (SEPA) with Yorkville provides access to up to $1 billion in capital, offering a reliable source of funding for general corporate purposes, including research and development and platform development.

Negatives

• The acquisition will result in substantial dilution for existing BioSig stockholders, with Streamex shareholders owning 75% of the fully diluted common equity post-approval.
• Streamex has a limited operating history and has incurred significant losses since inception, with a 'going concern' qualification from its independent auditors.
• The classification of Exchangeable Shares as derivative liabilities will result in earnings volatility due to fair value remeasurement each reporting period.
• The integration of a software-based, pre-commercial tokenization business into a legacy medical device company presents significant operational, technological, and cultural challenges.
• The success of the new business segment is uncertain, as Streamex's blockchain-based token offerings and smart contracts are not yet live, and market acceptance is unproven.
• The company's reliance on less liquid gold holdings as part of its treasury strategy may limit financial flexibility and resilience in times of operational or market stress.
• The potential for increased regulatory oversight across securities, commodities, and precious metals regimes could lead to significant compliance costs, delays, or restrictions on operations.

Risks

• Fluctuations in the price of gold and volatility in digital asset markets may adversely affect financial results and demand for tokenized gold products.
• Streamex has a limited operating history and has incurred significant losses since inception, raising substantial doubt about its ability to continue as a going concern.
• The gold-linked tokenization and treasury strategy may expose the company to complex liquidity risks across both traditional and digital asset markets.
• Operating in the highly competitive gold market, established participants with greater resources, regulatory positioning, or brand recognition may outperform the company.
• Evolving regulatory requirements for gold trading and cross-border transactions may increase compliance costs and restrict or delay operations.
• The ability to execute the business plan depends on the successful development, deployment, and commercialization of blockchain-based enterprise solutions, which may not materialize as expected.
• Changes in laws and regulations, including increased regulation of blockchain technologies and digital assets, may adversely affect the business, product development, and compliance obligations.
• The platform may fail to achieve market adoption or effectively address key inefficiencies in traditional gold and commodities markets.
• Discrepancies between token volume entitlements and actual gold delivery may lead to valuation uncertainty, settlement delays, and reputational harm.
• Concentration of holdings and strategy in gold may amplify inherent business model risks and expose the company to adverse market and operational developments.
• Gold holdings will be significantly less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity.
• Reliance on future gold production contracts exposes token holders to counterparty and delivery risks.
• The freely transferable nature of gold-backed tokens may increase market volatility and limit recourse for token holders in disputes or enforcement actions.
• Token holders bear the full economic risk of gold price fluctuations and potential non-performance by gold producers.
• The ability to build and scale a community of clients and investor end-users for blockchain-enabled financial services and products is uncertain.
• Streamex's bullion custody infrastructure is not yet operational and may not be finalized in a timely manner or with expected third-party providers.
• Streamex may not enter into relationships with LBMA-accredited custodians or vault providers, impacting gold integrity and investor confidence.
• Gold may be held on an unallocated basis, and there is no current mechanism to link tokens to individual bullion bars, introducing custody, transparency, and redemption risks.
• Streamex does not currently offer physical redemption for gold and may never provide such functionality, limiting utility and investor recourse.
• Streamex has not yet implemented an independent audit process for bullion holdings, and timing for audit implementation remains uncertain.
• Insurance coverage on the underlying gold will be arranged by the custodian, but specific coverage terms have not yet been disclosed or finalized.
• In the event of loss, theft, or damage to the gold, recovery of value may depend entirely on the custodian's insurance and operational reliability.
• Tokenholders may rank as unsecured creditors in an insolvency and may be subject to delays or losses in any distribution process.
• Streamex retains centralized control over the token smart contracts, including upgrade authority, which may result in operational or governance risks.
• There is no live proof-of-reserves dashboard or public confirmation of 1:1 gold backing for tokens at this time.
• Streamex may not prevent issuance of tokens in excess of gold held if smart contract or operational safeguards fail.
• Streamex's tokenized gold products are expected to be classified as securities, exposing Streamex to comprehensive and evolving regulatory obligations across multiple jurisdictions.
• Streamex has not received any no-action relief or regulatory approvals in the United States or other jurisdictions outside Canada, which may subject it to enforcement risk and limit its ability to operate.
• Onboarding is subject to AML/KYC procedures, but compliance infrastructure and enforcement mechanisms may be evolving or incomplete.
• Tokens are not currently listed on any exchange, and no market makers are engaged to provide liquidity or price stability.
• Streamex has not yet defined the transferability, lock-up restrictions, or resale mechanics applicable to its tokens.
• In the event the bullion custodian or Streamex ceases operations, tokenholders may suffer losses and may not recover their full holdings.
• If the company were deemed to be an investment company under the Investment Company Act of 1940, applicable restrictions could significantly limit business operations.
• The issuance of Exchangeable Shares in the Share Exchange will result in substantial dilution to existing BioSig stockholders.
• The Exchangeable Share structure introduces complexity and may create conflicts between Exchangeable Shareholders and BioSig stockholders.
• The Share Exchange is complex and entails risks related to shareholder approvals, Nasdaq listing, dilution, and market acceptance.
• There can be no assurance that the anticipated benefits of the Share Exchange will be realized.
• The classification of the Exchangeable Shares as derivative liabilities will result in earnings volatility and may adversely impact reported financial results.
• Integration of Streamex's operations into BioSig may disrupt ongoing operations and divert management attention.
• Reliance on contingent Exchangeable Shares and related exchange rights could restrict liquidity and complicate capital structure management.
• The success of the Combined Company depends in part on retaining key personnel of Streamex.
• Regulatory authorities may not agree with the company's conclusion that the Share Exchange should be accounted for as a business combination with BioSig as the accounting acquirer or with its assessment that BioSig was not a shell company prior to the transaction, which could subject the company to additional regulatory burdens, restatements, and limitations on future capital raising.

Future Outlook

The combined company intends to operate two principal business segments: healthcare innovation (PURE EP platform and ViralClear BioSciences) and tokenized finance/real-world asset digitization (Streamex). Streamex's primary focus for 2025 includes finalizing and deploying its tokenized gold financing product, securing regulatory approvals, establishing custodial partnerships, building capital markets access infrastructure, and expanding its team. The company anticipates continued operating losses in the near term as it invests in platform readiness and pursues regulatory milestones for its initial product suite. The company expects to raise at least $5 million in additional capital post-closing through various financing options.

Management Comments

• Henry McPhie, BioSig CEO: 'I urge you to submit your vote as soon as possible, even if you currently plan to attend the online-only meeting. Thank you for your support of our company. I look forward to seeing you at the Special Meeting.'
• BioSig Board of Directors: 'The Board has determined UNANIMOUSLY to recommend a vote FOR the Acquisition Proposal, FOR the approval of the Convertible Debenture Share Issuance Proposal, FOR the approval of the Plan Amendment Proposal, FOR the approval of the SEPA Share Issuance Proposal, FOR the approval of the Authorized Shares Proposal and FOR the approval of the Classified Board Proposal.'
• BioSig Board of Directors: 'The Share Exchange had the potential to result in a higher market valuation by virtue of combining a biotechnology company with a technology-focused digital asset platform, potentially leading the market to assign a higher trading multiple to a diversified business.'
• BioSig Board of Directors: 'The Share Exchange could provide enhanced flexibility for the monetization of non-core assets, and the Combined Company will have access to adjacent markets and digital asset infrastructure, creating potential new recurring or transactional revenue streams that are not dependent on traditional biotech cycles.'
• BioSig Board of Directors: 'Streamex's leadership brings technology and digital finance expertise that complements our biotech domain knowledge, enhancing the management team's overall execution capacity.'

Industry Context

This announcement signifies a major strategic pivot for BioSig Technologies, Inc., a medical device company, into the nascent and highly speculative real-world asset (RWA) tokenization and blockchain-enabled finance industry. This move aligns with a broader trend of traditional companies exploring blockchain technology for new revenue streams and asset digitization, as evidenced by competitors like Pax Gold (PAXG) and Securitize, Inc. However, it also places BioSig in a highly competitive and rapidly evolving landscape with established financial institutions, bullion banks, and emerging blockchain-native platforms. The shift from a regulated healthcare sector to a largely unregulated digital asset space introduces significant new regulatory and market adoption challenges.

Comparison to Industry Standards

• Streamex's business model, focusing on tokenized gold financing programs backed by future production contracts, is a relatively new approach compared to established gold-backed tokens like Pax Gold (PAXG), which issues tokens redeemable one-for-one for physical gold stored in LBMA vaults and has an $810 million market cap.
• Unlike more mature platforms, Streamex's bullion custody infrastructure is not yet operational, and it has not finalized relationships with LBMA-accredited custodians, which is a standard for ensuring gold integrity and investor confidence in the industry.
• The absence of physical redemption functionality for Streamex's tokens, and no current mechanism to link tokens to individual bullion bars, contrasts with some traditional gold investment products and more established tokenized offerings that provide direct physical settlement or granular traceability.
• Streamex's lack of an independent audit process for bullion holdings and no live proof-of-reserves dashboard falls short of best practices for transparency and trust-building in the asset-backed digital token space, where competitors often provide real-time attestations.
• The expectation that Streamex's tokenized gold products will be classified as securities in multiple jurisdictions, without having received no-action relief or regulatory approvals outside Canada, indicates a higher regulatory risk profile compared to entities that have secured such clarity or operate under more established regulatory frameworks like Securitize, Inc., a regulated issuer of security tokens with over $4 billion in tokenized assets.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the Proxy Statement, there are no material legal proceedings, and no contemplated legal proceedings known to be material, to Streamex, to which Streamex is a party or of which any of Streamex or its respective property is the subject matter.

Related Party Transactions

• On June 6, 2024, Streamex issued 83,333 shares to Morgan Lekstrom (Chairman of Streamex/BioSig) and 83,333 shares to Henry McPhie (CEO of Streamex/BioSig) for $0.15 per share, totaling $24,999.90.
• On November 26, 2024, Streamex issued 13,749,999 shares to Henry McPhie and 13,749,999 shares to Morgan Lekstrom for $0.0001 per share, and 1,950,000 shares to Sean Roosen (Streamex Director) for $0.025 per share.
• In connection with the Share Purchase Agreement, Henry McPhie, Morgan Lekstrom, and Mitch Williams, as Streamex shareholders, received 21,014,450, 20,707,421, and 937,382 Exchangeable Shares, respectively, on the same terms as other Streamex shareholders.
• As of March 31, 2025, Streamex had an accounts receivable of $15,000 owed from the CEO (Henry McPhie).
• As of March 31, 2025, Streamex had accounts payable of $10,478 due to the CEO (Henry McPhie) and $36,750 owed to a corporation controlled by the CFO.
• During the three months ended March 31, 2025, Streamex recognized $35,000 in consulting fees and $7,500 in accounting fees from related parties.
• On May 27, 2025, BioSig and Streamex entered into Finder Agreements with three finders, agreeing to issue BioSig Shares representing an aggregate of 3.75% of its outstanding shares immediately prior to the Closing as compensation for introductions.

Stakeholder Impact

• **Shareholders (Existing BioSig)**: Will experience substantial dilution, potentially reducing their percentage ownership and voting power from 100% to 25% of the fully diluted combined entity. The value of their holdings may be negatively impacted by the speculative nature of the new business and potential future dilutive capital raises.
• **Shareholders (Former Streamex)**: Will become the majority owners (75% fully diluted) of the combined public entity, gaining liquidity and a public listing for their investment in Streamex. They may benefit from potential tax deferrals through the exchangeable share structure.
• **Employees (BioSig)**: Significant management changes have occurred, with the former CEO/President/Chairman resigning and new leadership from Streamex taking over. The strategic pivot may lead to shifts in operational focus and potential restructuring, impacting existing BioSig employees.
• **Employees (Streamex)**: Their key personnel are critical to the success of the combined company, and their retention is a focus. The acquisition provides them with a public platform and potentially new incentive structures.
• **Customers (BioSig's PURE EP platform/ViralClear BioSciences)**: The diversion of management attention and resources to the new Streamex business segment could potentially impact the focus and development of BioSig's legacy healthcare products.
• **Customers (Streamex)**: The success of the new tokenized gold platform depends on attracting and retaining a community of clients and investor end-users, who will bear the economic risk of gold price fluctuations and counterparty non-performance.
• **Creditors (Yorkville)**: Yorkville is providing significant financing through convertible debentures ($100M) and a SEPA (up to $1B), secured by a first priority security interest in substantially all assets. Their investment is contingent on shareholder approvals, and they have specific conversion rights and protections.
• **Regulatory Authorities**: The strategic pivot into tokenized assets will subject the combined company to enhanced and evolving regulatory oversight across securities, commodities, and precious metals regimes in multiple jurisdictions, increasing compliance burdens and potential enforcement risks.

Next Steps

• Hold a Special Meeting of Stockholders on September 5, 2025, to vote on the Acquisition Proposal, Convertible Debenture Share Issuance Proposal, Plan Amendment Proposal, SEPA Share Issuance Proposal, Authorized Shares Proposal, and Classified Board Proposal.
• If Parent Stockholder Matters are approved, BioSig will file a registration statement on Form S-3 (or S-1) to register for resale the Exchangeable Shares.
• If Parent Stockholder Matters are approved, BioSig will amend its certificate of incorporation to increase authorized shares and classify the board.
• If Parent Stockholder Matters are approved, BioSig will adopt or amend a new stock incentive plan (New Incentive Plan) reserving 10% of fully-diluted equity for issuance.
• Streamex plans to finalize and deploy its tokenized gold financing product, including onboarding mining counterparties and implementing smart contracts.
• Streamex aims to secure regulatory approvals or exemptions for the issuance and distribution of gold-backed tokens in Canada and select global jurisdictions.
• Streamex intends to establish partnerships with London Bullion Market Association-accredited custodians and launch a proof-of-reserves system.
• Streamex plans to build out capital markets access infrastructure for institutional and qualified investors.
• Streamex expects to expand its team to support technology, compliance, and commercial functions.
• The company will file an initial listing application for BioSig Shares with Nasdaq, if required by change of control rules.

Key Dates

Recommendation

The filing reveals a distressed medical device company (BioSig) acquiring a pre-revenue, loss-making blockchain startup (Streamex) with a 'going concern' qualification. This strategic pivot is highly speculative and introduces immense risk. The proposed transaction will result in severe dilution for existing BioSig shareholders, reducing their ownership to 25% of the combined entity. Furthermore, the company is seeking approval for substantial, potentially highly dilutive, capital raises (up to $1 billion via SEPA and $100 million in convertible debentures) to fund the new, unproven business. The combination of extreme dilution, high operational risk in a nascent and unregulated industry, and a clear need for significant future capital, suggests a very poor outlook for current shareholders. Seasoned investors would likely exit positions given the fundamental shift and adverse financial implications.

Keywords

Tokenized Assets, Real-World Assets, Blockchain, Gold Tokenization, Digital Assets, SEC Filing, Proxy Statement, Shareholder Meeting, Dilution, Capital Raise, Convertible Debentures, Standby Equity Purchase Agreement, Corporate Governance, Management Change, Nasdaq Listing, Risk Factors, Fintech, Medical Device